http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-083628-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ecaa35143dd955d729ebd927025e6263 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b70d34c1ba8add90eaa4b2b6f9678265 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d1c3a385135699d6dfb7fe4c2d39fbf |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-431 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5161 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-431 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
| filingDate | 2011-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_177f3c048fd511db2207be70cc69a87a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b67fd6c059add64fcab87725bcf31a25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ed9a919bb24bdf5f8da093633ee4d66 |
| publicationDate | 2013-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-083628-A1 |
| titleOfInvention | NANOPARTICULATED COMPOSITION CONTAINING ANTIBIOTICS FOR INTRAMAMARY ADMINISTRATION FOR ANIMAL USE |
| abstract | Process for the preparation of colloidal suspensions for veterinary use with sizes ranging from 100 to 800 hm, which are suitable for transporting to benzathine cloxacillin with application for the treatment or prophylaxis of mastitis in animals during the dry period by intramammary administration. 1: Process for the preparation of colloidal suspensions for veterinary use with sizes ranging from 100 to 800 hm, which are suitable for transporting to benzathine cloxacillin with application for the treatment or prophylaxis of mastitis in animals during the dry period by intramammary administration characterized in that the said process comprises nanotransporters containing an oily or pasty core of submicron dimensions covered by a polymeric membrane that originates nanoreservoirs, nanoenvoltories and nanotransporters dispersed in an external aqueous medium, where the process comprises: a solution that co it has a hydrophobic polymer insoluble in water, oil and surfactant dissolved in water-miscible organic solvents; a neutral aqueous solution may contain surfactant and / or cationic polymer in the form of a water soluble salt; the simultaneous combination of the aqueous and the oily phase forms the nanogrobes that are coated by a polymeric film, where for the coated nanoreservices, the adsorption of the cationic polymer to the particle occurs by electrostatic attraction between the hydrophobic polymer and the cationic polymer to provide particles with positive surface charge. Claim 2: Conventional nanoreservories constituted by an oily core wrapped by a polymeric membrane, according to what is defined in claim 1 characterized by being transporters of antibacterial agents, preferably benzathine cloxacillin, for the treatment and prevention of inflammatory and infectious foci. in the mammary gland of animals in the dry period. Claim 3: Conventional chitosan-coated nanoreservice, its water-soluble salts or neutral derivatives, according to claim 1, consisting of an oily core wrapped by a polymeric membrane, characterized by the ability of bioadhesion to the cells inside the udder animal, as well as being transporters of antibacterial agents, preferably cloxacillin benzathine, for the treatment and prevention of inflammatory and infectious foci in the mammary gland of animals in the dry period. Claim 6: Composition according to claim 5, characterized in that the oily core is composed of medium chain triglyceride, such as capric / caprylic acid triglyceride, or fatty acid esters of 6 to 18 carbon atoms or oils of vegetable origin, such as soybean oil, corn, cotton, olive, almond, sunflower, grape or mineral oil such as liquid paraffin, or polyglyceryl-6 dioleate or polyethylene glycol-6 of olive or almond oil or of corn Claim 7: Nanotransporters according to claim 1, characterized in that they contain in their composition stable hydrophobic polymers inside the mammary gland, for being biocompatible and biodegradable, such as: polyesters of lactic, glycolic acids and their co-polymers and its different combinations and proportions with molecular weight varying between 2000 and 100,000 namely: poly-e-caprolactone (PCL), diblock and multiblock polymers derived from polymers (poly (latic) acid (PLA), poly (lactic-co-glycolic) (PLGA), polyglycolic acid (PGA), polyhydroxyalkanoates (PHA), poly-b-hydroxybutyrate, poly-b- (hydroxybutyrate-co-valerate). Claim 10: Composition, according to claims 1, 2 and 3, characterized in that the percentage of hydrophilic surfactant varies from 0 to 2% w / v in relation to the final volume of the aqueous medium which can be polysorbate 20 or 21 or 40 or 60 or 61 or 65 or 80 or 81 or 85 or 120; or it may be a derivative of the ethylene-propylene polyoxide polyoxide copolymer such as poloxamer 124 or 188 or 237 or 338 or 407. Claim 11: Composition according to claims 1, 2 and 3, characterized in that that the percentage of lipophilic surfactant ranges from 0.1 to 2% w / v in relation to the final volume of the aqueous medium, which may be a derivative of sorbitan esters such as sorbitan monolaureate, sorbitan trilaureate, monopalmitate sorbitan, sorbitan monostearate, sorbitan triestearate, sorbitan monooleate, sorbitan trioleate; or a derivative of lecithin, such as soy lecithin. Claim 12: Polymeric nanoreservices, according to claims 1 to 11, characterized in that they contain antibiotic cloxacillin benzathine (and / or derivatives) which can be administered orally, parenterally, ocularly and / or combination of these routes . Claim 18: Method according to claim 1, characterized in that the nanotransporters are prepared by a method using two organic solvents miscible with water where the veterinary antibiotic is present. Claim 19: Method according to claim 18, characterized in that the organic phase is mixed with a neutral aqueous phase that may contain surfactants, the total solvents being evaporated to less than one third of the total volume of the mixture at end of the process Claim 25: Method according to claims 23 and 24, characterized in that different types of cryoprotectants are used, such as glucose, sucrose, trehalose, lactose, fructose, maltose, polydextrose, glycerol, sorbitol, chitosan and its derivatives, gelatin, colloidal silicon dioxide and / or mixture of the components mentioned above. Claim 26: Method according to claim 25, characterized in that cryoprotectant concentrations of up to 80% (w / w) are added to the preparation to be lyophilized to obtain a suitable resuspension with maintenance of the physicochemical characteristics . Claim 29: Conventional nanoreservories constituted by an oily core wrapped by a polymeric membrane, according to claims 1, 2 and 28 characterized by being transporters of antibacterial, antifungal, antiparasitic, vitamin, non-steroidal anti-inflammatory, steroidal anti-inflammatory, anti-viral agents, antineoplastic, anesthetic and hormones for the treatment or prophylaxis of diseases of non-human animals. Claim 30: Conventional chitosan-coated nanoreservice, its water-soluble salts or neutral derivatives, according to claims 1, 3 and 28, characterized in that it is constituted of an oily core wrapped by a polymeric membrane, characterized by having bioadhesion capacity to cells that have negatively charged proteoglycans on their surface, as well as being transporters of antibacterial, antifungal, antiparasitic agents, vitamins, non-steroidal anti-inflammatory, steroidal anti-inflammatory, anti-viral, anti-neoplastic, anesthetic and treatment hormones or prophylaxis of diseases of non-human animals. |
| priorityDate | 2010-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.